Amanote Research
Register
Sign In
Axitinib Plus Pembrolizumab Is Effective in Renal Cell Carcinoma
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2018-032
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
February 23, 2018
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Axitinib for the Management of Metastatic Renal Cell Carcinoma
Drugs in R and D
Pharmacology
Pharmacoeconomic Evaluation of Axitinib Introduction in Metastatic Renal Cell Carcinoma Treatment Scheme
Pharmacoeconomics: theory and practice
Extended Progression-Free Survival of Renal Cell Carcinoma With Axitinib: Case Report
Journal of Urology and Renal Diseases
Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
Pembrolizumab Yields Lasting Merkel Cell Carcinoma Responses
Cancer Discovery
Oncology
Epacadostat Plus Pembrolizumab Is Well Tolerated in a Phase I Trial
Cancer Discovery
Oncology
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
Cancer Research and Treatment
Cancer Research
Oncology
Pembrolizumab Is Effective for Drug-Resistant Gestational Trophoblastic Neoplasia
The Lancet
Medicine
Renal Cell Carcinoma
World Journal of Urology
Urology
